Drug
Baricitinib
Baricitinib: highest development phase Phase 3, developed by Eli Lilly. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Baricitinib NCT03334435 | Phase 3 | Atopic Dermatitis |
| Baricitinib NCT03952559 | Phase 3 | Atopic Dermatitis |
| Baricitinib suspension NCT03212638 | Phase 1 | Healthy |
Latest
No recent events.
Follow Baricitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.